GILEAD SCIENCES, INC. Debt Securities, Available-for-sale, Amortized Cost
GILEAD SCIENCES, INC. (GILD) had Debt Securities, Available-for-sale, Amortized Cost of $2.48 billion as of 2021-03-31, per its 10-Q filed 2021-05-06.
Discontinued › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2021-05-06
- 2021-03-31: Debt Securities, Available-for-sale, Amortized Cost $2.48B.
- 2020-12-31: Debt Securities, Available-for-sale, Amortized Cost $2.02B.
- 2020-09-30: Debt Securities, Available-for-sale, Amortized Cost $13.37B.
- 2020-06-30: Debt Securities, Available-for-sale, Amortized Cost $14.88B.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2021-03-31 | $2.48B 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $2.02B 10-Q · filed 2021-05-06 | |
| 2020-09-30 | $13.37B 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $14.88B 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $14.95B 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $16.50B 10-K · filed 2021-02-25 | |
| 2019-09-30 | $19.05B 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $25.06B 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $24.54B 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $24.22B 10-K · filed 2020-02-25 | |
| 2018-09-30 | $23.52B 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $22.66B 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $24.79B 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $29.68B 10-K · filed 2019-02-26 | $34.40B 10-K · filed 2018-02-27 |
| 2017-09-30 | $39.42B 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $34.80B 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $31.88B 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $29.97B 10-K · filed 2017-02-27 | |
| 2016-09-30 | $29.15B 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $22.53B 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $17.15B 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $23.57B 10-K · filed 2016-02-24 | |
| 2014-12-31 | $9.63B 10-K · filed 2015-02-25 | |
| 2014-09-30 | $6.54B 10-Q · filed 2014-11-05 | |
| 2014-06-30 | $6.74B 10-Q · filed 2014-08-04 | |
| 2014-03-31 | $5.51B 10-Q · filed 2014-05-07 | |
| 2013-12-31 | $1.95B 10-Q · filed 2014-11-05 | |
| 2013-09-30 | $2.31B 10-Q · filed 2013-10-31 | |
| 2013-06-30 | $2.64B 10-Q · filed 2013-08-01 | |
| 2012-12-31 | $2.19B 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |